{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:55:02Z","timestamp":1792144502611,"version":"4.4.0"},"reference-count":20,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Although drugs are a common cause of acute immune-mediated thrombocytopenia in adults, the drug etiology is often initially unrecognized. Most cases of drug-induced thrombocytopenia (DITP) are caused by drug-dependent antibodies that are specific for the drug structure and bind tightly to platelets by their Fab regions but only in the presence of the drug. A comprehensive database of 1301 published reports describing 317 drugs, available at www.ouhsc.edu\/platelets, provides information on the level of evidence for a causal relation to thrombocytopenia. Typically, DITP occurs 1 to 2 weeks after beginning a new drug or suddenly after a single dose when a drug has previously been taken intermittently. However, severe thrombocytopenia can occur immediately after the first administration of antithrombotic agents that block fibrinogen binding to platelet GP IIb-IIIa, such as abciximab, tirofiban, and eptifibatide. Recovery from DITP usually begins within 1 to 2 days of stopping the drug and is typically complete within a week. Drug-dependent antibodies can persist for many years; therefore, it is important that the drug etiology be confirmed and the drug be avoided thereafter.<\/jats:p>","DOI":"10.1182\/asheducation-2009.1.153","type":"journal-article","created":{"date-parts":[[2009,12,11]],"date-time":"2009-12-11T15:35:31Z","timestamp":1260545731000},"page":"153-158","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":222,"title":["Drug-induced thrombocytopenia: pathogenesis, evaluation, and management"],"prefix":"10.1182","volume":"2009","author":[{"given":"James N.","family":"George","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H.","family":"Aster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111705390712400_R1","doi-asserted-by":"crossref","unstructured":"George JN, Raskob GE, Shah SR, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Int Med. 1998;129:886\u2013890.","DOI":"10.7326\/0003-4819-129-11_Part_1-199812010-00009"},{"key":"2019111705390712400_R2","doi-asserted-by":"crossref","unstructured":"Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med. 2007;357:580\u2013587.","DOI":"10.1056\/NEJMra066469"},{"key":"2019111705390712400_R3","doi-asserted-by":"crossref","unstructured":"Aster RH, Curtis BR, McFarland JG, Bougie DW. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis and management. J Thromb Haemost. 2009;7:911\u2013918.","DOI":"10.1111\/j.1538-7836.2009.03360.x"},{"key":"2019111705390712400_R4","doi-asserted-by":"crossref","unstructured":"Arnold J, Ouwehand WH, Smith G, Cohen H. A young woman with petechiae. Lancet. 1998;352:618.","DOI":"10.1016\/S0140-6736(98)05194-0"},{"key":"2019111705390712400_R5","doi-asserted-by":"crossref","unstructured":"Azuno Y, Yaga K, Sasayama T, Kimoto K. Thrombocytopenia induced by Jui, a traditional Chinese herbal medicine. Lancet. 1999;354:304\u2013305.","DOI":"10.1016\/S0140-6736(99)01336-7"},{"key":"2019111705390712400_R6","doi-asserted-by":"crossref","unstructured":"Ohmori T, Nishii K, Hagihara A, Takeda M, Sekido K. Acute thrombocytopenia induced by Jui, a traditional herbal medicine. J Thromb Haemost. 2004;2:1479\u20131480.","DOI":"10.1111\/j.1538-7836.2004.00786.x"},{"key":"2019111705390712400_R7","unstructured":"Kojouri K, Perdue JJ, Medina PJ, George JN. Occult quinine-induced thrombocytopenia. J Okla State Med Assoc. 2000;93:519\u2013521."},{"key":"2019111705390712400_R8","doi-asserted-by":"crossref","unstructured":"Reddy JC, Shuman MA, Aster RH. Quinine\/quinidine-induced thrombocytopenia: a great imitator. Arch Intern Med. 2004;164:218\u2013220.","DOI":"10.1001\/archinte.164.2.218"},{"key":"2019111705390712400_R9","doi-asserted-by":"crossref","unstructured":"Gottschall JL, Neahring B, McFarland JG, et al. Quinine-induced immune thrombocytopenia with hemolytic uremic syndrome: clinical and serological findings in nine patients and review of literature. Am J Hematol. 1994;47:283\u2013289.","DOI":"10.1002\/ajh.2830470407"},{"key":"2019111705390712400_R10","doi-asserted-by":"crossref","unstructured":"Kojouri K, Vesely SK, George JN. Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes. Ann Int Med. 2001;135:1047\u20131051.","DOI":"10.7326\/0003-4819-135-12-200112180-00008"},{"key":"2019111705390712400_R11","doi-asserted-by":"crossref","unstructured":"Bougie DW, Wilker PR, Aster RH. Patients with quinine-induced immune thrombocytopenia have both \u201cdrug-dependent\u201d and drug-specific\u201d antibodies. Blood. 2006;108:922\u2013927.","DOI":"10.1182\/blood-2006-01-009803"},{"key":"2019111705390712400_R12","doi-asserted-by":"crossref","unstructured":"Peterson JA, Nelson TN, Kanack AJ, Aster RH. Fine specificity of drug-dependent antibodies reactive with a restricted domain of platelet GP IIIa. Blood. 2008;111:1234\u20131239.","DOI":"10.1182\/blood-2007-09-112680"},{"key":"2019111705390712400_R13","doi-asserted-by":"crossref","unstructured":"Gao C, Curtis BR, Bougie DW, et al. Eptifibatide-induced thrombocytopenia and thrombosis in humans require Fc\u03b3RIIa and the integrin b3 cytoplasmic domain. J Clin Invest. 2009;119:504\u2013511.","DOI":"10.1172\/JCI36745"},{"key":"2019111705390712400_R14","doi-asserted-by":"crossref","unstructured":"Curtis BR, Divgi A, Garrity MM, Aster RH. Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug. J Thromb Haemost. 2004;2:985\u2013992.","DOI":"10.1111\/j.1538-7836.2004.00744.x"},{"key":"2019111705390712400_R15","doi-asserted-by":"crossref","unstructured":"Belkin GA. Cocktail purpura: an unusual case of quinine sensitivity. Ann Intern Med. 1967;66:583.","DOI":"10.7326\/0003-4819-66-3-583"},{"key":"2019111705390712400_R16","doi-asserted-by":"crossref","unstructured":"Lavy R. Thrombocytopenic purpura due to Lupinus termis bean. J Allergy Clin Immunol. 1964;35:386\u2013388.","DOI":"10.1016\/0021-8707(64)90065-6"},{"key":"2019111705390712400_R17","doi-asserted-by":"crossref","unstructured":"Neylon AJ, Saunders PWG, Howard MR, Proctor SJ, Taylor PRA. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol. 2003;122:966\u2013974.","DOI":"10.1046\/j.1365-2141.2003.04547.x"},{"key":"2019111705390712400_R18","doi-asserted-by":"crossref","unstructured":"Curtis BR, Kaliszewski J, Marques MB, et al. Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am J Hematol. 2006;81:193\u2013198.","DOI":"10.1002\/ajh.20516"},{"key":"2019111705390712400_R19","doi-asserted-by":"crossref","unstructured":"Kaufman DW, Kelly JP, Johannes CB, et al. Acute thrombocytopenic purpura in relation to the use of drugs. Blood. 1993;82:2714\u20132718.","DOI":"10.1182\/blood.V82.9.2714.2714"},{"key":"2019111705390712400_R20","doi-asserted-by":"crossref","unstructured":"Li X, Aster RH, Curtis BR, et al. Detecting drugs that cause thrombocytopenia: a comparison of three methods [1] published case reports, [2] tests for drug-dependent anti-platelet antibodies, [3] data mining of the US FDA Adverse Event Reporting System database [abstract]. Blood. 2007;118:621\u2013622.","DOI":"10.1182\/blood.V110.11.2087.2087"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2009\/1\/153\/645424\/153_158ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2009\/1\/153\/645424\/153_158ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T02:22:03Z","timestamp":1590286923000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2009\/1\/153\/19800\/Druginduced-thrombocytopenia-pathogenesis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2009.1.153","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,1]]}}}